Plaque-type dura mater graft-associated Creutzfeldt-Jakob disease: an autopsied case report.

PrionFeb 28, 2026 (epub)
Case ReportNeurologyOpen access

Daisuke Tahara, Daichi Yokoi, Nao Tahara et al.

✦ AI-curated · Sources linked

Case in brief

A 41-year-old man developed right-hand paraesthesia 27 years after receiving a right parietal dural graft following traumatic subdural haematoma. His illness progressed slowly, with loss of independent walking, cognitive decline, myoclonus and akinetic mutism; EEG never showed periodic sharp-wave complexes. Genetic testing found no prion protein gene mutation, with methionine homozygosity at codon 129. Autopsy showed spongiform change, neuronal loss and astrogliosis, with broadly distributed abnormal prion protein deposits, including plaques and prominent staining in spinal grey matter. Intermediate-type prion protein was detected in brain and cervical cord, but not systemic organs.

What made this case unusual

The combination of a slowly progressive course without periodic sharp-wave complexes and intense abnormal prion protein staining throughout spinal grey matter informed the authors’ suggestion that transmission may have occurred indirectly via a peripheral route rather than directly from the graft to the central nervous system.

Diagnostic / clinical pearl

Dura mater graft-associated CJD may have a slowly progressive presentation without periodic sharp-wave complexes; their absence did not exclude the diagnosis in this case.

Source

Published in Prion. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.